DE69733968D1 - Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen - Google Patents

Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen

Info

Publication number
DE69733968D1
DE69733968D1 DE69733968T DE69733968T DE69733968D1 DE 69733968 D1 DE69733968 D1 DE 69733968D1 DE 69733968 T DE69733968 T DE 69733968T DE 69733968 T DE69733968 T DE 69733968T DE 69733968 D1 DE69733968 D1 DE 69733968D1
Authority
DE
Germany
Prior art keywords
norbornandiols
norborn
treatment
diseases
proliferative skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69733968T
Other languages
English (en)
Other versions
DE69733968T2 (de
Inventor
A Brown
A Khorlin
Krystyna Lesiak
Yun Ren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Genetics Inc
Original Assignee
Applied Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Genetics Inc filed Critical Applied Genetics Inc
Application granted granted Critical
Publication of DE69733968D1 publication Critical patent/DE69733968D1/de
Publication of DE69733968T2 publication Critical patent/DE69733968T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69733968T 1996-09-18 1997-09-18 Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen Expired - Lifetime DE69733968T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US2657796P 1996-09-18 1996-09-18
US26577P 1996-09-18
US3594797P 1997-01-21 1997-01-21
US35947P 1997-01-21
US3686397P 1997-02-04 1997-02-04
US36863P 1997-02-04
US4859797P 1997-06-04 1997-06-04
US48597P 1997-06-04
PCT/US1997/016642 WO1998011882A1 (en) 1996-09-18 1997-09-18 Pharmaceutical compositions and methods

Publications (2)

Publication Number Publication Date
DE69733968D1 true DE69733968D1 (de) 2005-09-15
DE69733968T2 DE69733968T2 (de) 2006-06-01

Family

ID=27487517

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733968T Expired - Lifetime DE69733968T2 (de) 1996-09-18 1997-09-18 Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen

Country Status (9)

Country Link
US (2) US5990177A (de)
EP (1) EP0957903B1 (de)
AT (1) ATE301459T1 (de)
AU (1) AU740783B2 (de)
CA (1) CA2266496A1 (de)
DE (1) DE69733968T2 (de)
DK (1) DK0957903T3 (de)
ES (1) ES2245465T3 (de)
WO (1) WO1998011882A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214888B1 (en) 1996-09-18 2001-04-10 Applied Genetics Incorporated Dermatological compounds
EP0957903B1 (de) 1996-09-18 2005-08-10 Applied Genetics Incorporated Dermatics Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen
US6623724B2 (en) * 1996-09-18 2003-09-23 Applied Genetics Incorporated Dermatics Dermatological compositions and methods
EP1001677A4 (de) * 1997-02-04 2003-01-08 Gen Hospital Corp Verfahren zur behandlung von epidermalen oder dermalen hautzuständen
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US6267948B1 (en) 1998-04-06 2001-07-31 Applied Genetics Incorporated Dermatics Dermatological formulations and methods
EP1087782A4 (de) * 1998-06-15 2001-09-12 Neuronz Ltd Regulation der tyrosinhydroxylase
IL132366A0 (en) * 1998-10-15 2001-03-19 Cell Pathways Inc Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds
US6359153B1 (en) * 1998-10-28 2002-03-19 Hyundai Electronics Industries Co., Ltd. Photoresist monomers and preparation thereof
WO2001068576A1 (en) * 2000-03-10 2001-09-20 Applied Genetics Incorporated Dermatics Dermatological compounds
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
DE10111050A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigenOrganismus ihre Wirkung entfaltet, zur Herstellung von kosmetischewn oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe unerwünschter Hautpigmentierung
US6682753B2 (en) * 2001-03-23 2004-01-27 Neuronz Limited Methods for promoting weight gain using GPE-related compounds
DE60232880D1 (de) 2001-05-24 2009-08-20 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US7714020B2 (en) * 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US20040192638A1 (en) * 2001-07-02 2004-09-30 Oaks John A. Method and composition for prolonging the residence time of drugs in the gut
AU2002320244A1 (en) * 2001-07-02 2003-01-21 Wisconsin Alumni Research Foundation Method and composition for prolonging the residence time of drugs in the gut
US6723755B2 (en) * 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
FR2840530B1 (fr) * 2002-06-11 2004-12-24 Oreal Composition cosmetique comprenant un agent inducteur de l'expression de la dopachrome tautomerase (trp-2) pour lutter contre la canitie
AU2004242507B2 (en) * 2002-06-12 2009-02-19 Piotr Chomczynski Method of treating rosacea
WO2003105864A1 (en) * 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
FR2856926B1 (fr) * 2003-07-02 2005-09-30 Centre Nat Rech Scient Utilisation des n-alkanols comme activateurs du canal cftr
US10350428B2 (en) 2014-11-04 2019-07-16 Endonovo Therapetics, Inc. Method and apparatus for electromagnetic treatment of living systems
US9433797B2 (en) 2003-12-05 2016-09-06 Rio Grande Neurosciences, Inc. Apparatus and method for electromagnetic treatment of neurodegenerative conditions
US9440089B2 (en) 2003-12-05 2016-09-13 Rio Grande Neurosciences, Inc. Apparatus and method for electromagnetic treatment of neurological injury or condition caused by a stroke
US8961385B2 (en) 2003-12-05 2015-02-24 Ivivi Health Sciences, Llc Devices and method for treatment of degenerative joint diseases with electromagnetic fields
US9656096B2 (en) 2003-12-05 2017-05-23 Rio Grande Neurosciences, Inc. Method and apparatus for electromagnetic enhancement of biochemical signaling pathways for therapeutics and prophylaxis in plants, animals and humans
US9415233B2 (en) 2003-12-05 2016-08-16 Rio Grande Neurosciences, Inc. Apparatus and method for electromagnetic treatment of neurological pain
NZ551316A (en) 2004-04-19 2008-03-28 Ivivi Technologies Inc Electromagnetic treatment apparatus and method
AU2005247948A1 (en) * 2004-05-27 2005-12-08 Migenix Corp. 2-substituted 17-imino estrogen compounds for cytoprotection
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
US9579298B2 (en) * 2004-12-02 2017-02-28 Piotr Chomczynski Antioxidant dietary supplement compositions and methods for maintaining healthy skin
FR2889808B1 (fr) 2005-08-17 2011-07-22 Oreal Utilisation de l'acide 8-hexadecene-1,16-dicarboxylique comme agent de soin destine a favoriser la cohesion de la couche cornee
US20090325911A1 (en) * 2005-10-21 2009-12-31 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of Androgens for the Treatment of Parkinson's Disease
KR101111020B1 (ko) * 2006-07-04 2012-03-13 주식회사 알엔에스 신규한 사이클릭 화합물의 유도체 및 그의 용도
EP2066393A1 (de) * 2006-09-20 2009-06-10 IVIVI Technologies, Inc. Elektromagnetische vorrichtung zur behandlung von atmungserkrankungen und verwendungsverfahren dafür
US20080229374A1 (en) * 2007-02-22 2008-09-18 Mick Colin K Video network including method and apparatus for high speed distribution of digital files over a network
CA2685202C (en) 2007-03-23 2017-11-28 The Board Of Regents Of The University Of Texas System Methods for treating allergic asthma
US8026217B2 (en) * 2007-10-03 2011-09-27 Florida Atlantic University Compositions and methods for treating neural anoxia and spreading depression
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
KR101050429B1 (ko) * 2009-03-18 2011-07-19 연세대학교 산학협력단 캠펜을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물
CN101797243B (zh) * 2010-03-23 2012-01-18 广东药学院 一种含有左旋多巴和冰片的组合物及其应用
CN104557568B (zh) * 2010-05-27 2017-04-12 塔加西普特公司 烟碱受体非竞争性拮抗剂
CA2813036A1 (en) 2010-10-01 2012-04-05 Ivivi Health Sciences, Llc Method and apparatus for electromagnetic treatment of head, cerebral and neural injury in animals and humans
ITMI20111260A1 (it) * 2011-07-06 2013-01-07 Carmelo Cutrupi Composizioni topiche per l'uso nella prevenzione e/o nel trattamento di dermatiti
US8343027B1 (en) 2012-01-30 2013-01-01 Ivivi Health Sciences, Llc Methods and devices for providing electromagnetic treatment in the presence of a metal-containing implant
EP2970109A4 (de) * 2013-03-12 2017-01-18 Bio-Pharm Solutions Co., Ltd. Phenylcarbamatverbindung und neuroprotektionszusammensetzung damit
WO2015161063A1 (en) 2014-04-16 2015-10-22 Iviv Health Sciences, Llc A two-part pulsed electromagnetic field applicator for application of therapeutic energy
CN105693817B (zh) * 2014-11-27 2020-06-05 西北大学 一类三肽化合物及其制备方法与应用
US10806942B2 (en) 2016-11-10 2020-10-20 Qoravita LLC System and method for applying a low frequency magnetic field to biological tissues

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT279052B (de) 1968-08-08 1970-02-25 Dragoco Gerberding Co Gmbh Lichtschutzmittel
DE2350315C2 (de) * 1973-10-06 1984-01-12 Johnson & Johnson GmbH, 4000 Düsseldorf Pharmazeutische und kosmetische Präparate zur äußerlichen Anwendung
US3956361A (en) 1974-05-23 1976-05-11 Ciba-Geigy Corporation Hindered phenolic derivatives of norbornane thioalcohols
US4102995A (en) * 1976-05-13 1978-07-25 Westwood Pharmaceuticals Inc. Tar gel formulation
DE3025187A1 (de) * 1980-07-03 1982-02-11 Henkel KGaA, 4000 Düsseldorf Neue riechstoffe, deren herstellung sowie diese enthaltende riechstoffkompositionen
US4647585A (en) 1984-11-08 1987-03-03 E. R. Squibb & Sons, Inc. Bicycloheptane substituted ethers
SE462139B (sv) * 1986-02-04 1990-05-14 Sven Moberg Farmaceutisk komposition, innehaallande propylenglykol och karbamid, foer behandling av bl.a. nagelsvamp och seborroiskt eksem
US5525635A (en) * 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
DE3724691C2 (de) * 1987-07-25 1999-03-18 Konrad Minninger Pharmazeutisches Mittel zur lokalen Therapie von schuppenden Hautkrankheiten
US5700450A (en) * 1988-03-30 1997-12-23 The Trustees Of Boston University Methods for enhancing melanin synthesis in melanocytes using diacyglycerols and uses thereof
US5352440A (en) * 1988-03-30 1994-10-04 Trustees Of Boston University Methods for increasing melanin content in melanocytes using diacylglycerols and uses thereof
DE3925634A1 (de) * 1989-08-03 1991-02-07 Bayer Ag Stabilisatordispersionen
US5190978A (en) * 1989-09-29 1993-03-02 Dai-Ichi Kogyo Seiyaku Co. Ltd. Carcinostatic compositions and methods
JP3013540B2 (ja) 1990-09-18 2000-02-28 住友化学工業株式会社 害虫忌避剤
US5190798A (en) * 1992-01-09 1993-03-02 Gilbert Bloch Paper-plastic film, fiberglass-reinforced sealing tape
US5414019A (en) 1992-04-09 1995-05-09 Wisconsin Alumni Research Foundation Regression of mammalian carcinomas
US5587402A (en) 1992-04-09 1996-12-24 Wisconsin Alumni Research Foundation Regression of mammalian leukemia cell tumors
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
US5470577A (en) * 1993-07-07 1995-11-28 Trustees Of Boston University Stimulation of tanning by DNA fragments or single-stranded DNA
EP0643113B1 (de) * 1993-09-09 2001-11-28 E.I. Du Pont De Nemours And Company Wässrige Tintenzusammensetzung, die Mittel gegen das Einrollen von Papier enthält
US5434144A (en) * 1994-03-04 1995-07-18 The Procter & Gamble Company Methods of using cyclic polyanionic polyol derivatives for regulating skin wrinkles
US5626839A (en) * 1994-11-08 1997-05-06 Scales-Medeiros; Virginia Light responsive self-tanning products and methods for use
MX9800379A (es) * 1995-07-11 1998-03-31 Procter & Gamble Composiciones suavizadoras de telas, estables, dispersables en agua, concentradas.
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
EP0967967B1 (de) * 1996-02-21 2002-07-10 Stoa S.A. Kosmetische, dermopharmazeutische oder tierärztliche zusammensetzungen zur antiseptischen behandlung von menschlicher oder tierischer haut
WO1998055085A1 (en) * 1997-06-04 1998-12-10 Codon Pharmaceuticals, Inc. Pharmaceutical compositions and methods
EP0957903B1 (de) 1996-09-18 2005-08-10 Applied Genetics Incorporated Dermatics Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen
ES2297892T3 (es) * 1997-08-21 2008-05-01 JOHNSON & JOHNSON CONSUMER COMPANIES, INC. Utilizacion de 17-beta-estradiol para el tratamiento de las pieles envejecidas o dañadas por el sol y/o atrofia de la piel.

Also Published As

Publication number Publication date
CA2266496A1 (en) 1998-03-26
AU4584297A (en) 1998-04-14
AU740783B2 (en) 2001-11-15
EP0957903A4 (de) 2002-10-09
ES2245465T3 (es) 2006-01-01
WO1998011882A1 (en) 1998-03-26
EP0957903A1 (de) 1999-11-24
US5990177A (en) 1999-11-23
US6294585B1 (en) 2001-09-25
EP0957903B1 (de) 2005-08-10
DE69733968T2 (de) 2006-06-01
DK0957903T3 (da) 2005-11-21
ATE301459T1 (de) 2005-08-15

Similar Documents

Publication Publication Date Title
DE69733968D1 (de) Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69932600D1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
ATE397621T1 (de) Hemmer der interaktion zwischen p53 und mdm2
DE3860043D1 (de) Verwendung von biertreberextrakt zur herstellung von medizinischen und kosmetischen zubereitungen.
EA200200990A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы дельта человека
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
ATE354372T1 (de) Verwendung von mif-antagonisten zur krebstherapie
DE69911210D1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
DE69621243D1 (de) Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls
DE69803200D1 (de) Verwendung von mindestens einen chrysanthemum gattungs extrakten zur förderung der haut- und/oder der haarepigmentierung
ATE222101T1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
DE69130679D1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
HUP0300923A2 (hu) RAF és RAS protein kinázt tartalmazó készítmények és alkalmazásuk angiogenezis módosítására
DE69900774T2 (de) Verwendung von topische präparationen mit glyceryl trinitrat und lanolin zur behandlung von erektilen funktionsstörungen
DE3775278D1 (de) Topische methotrexatzubereitung zur behandlung hyperproliferativer epithelerkrankungen.
NO20000007D0 (no) Anvendelse av veksthormon i sammensetninger til behandling av insulinresistens i hjertet samt for å oeke proteinkinase-B(PKB)- aktivitet
ATE358490T1 (de) Verwendung einer kombination aus einem purin und einem no-donor zur behandlung und prophylaxe sexueller funktionsstörungen
HUP0101602A2 (hu) Termékenységet javító készítmény, és annak alkalmazása

Legal Events

Date Code Title Description
8364 No opposition during term of opposition